Adjunctive terlipressin versus placebo in the treatment of refractory septic shock: a randomized, placebo-controlled trial
Primary resultResult — go to the resultRelative risk 1.53 95% CI 1.09–2.14Authors' conclusion
Among patients with refractory septic shock, adjunctive terlipressin reduced the proportion of patients requiring high-dose catecholamines at 6 h, without significantly altering mortality or digital ischemia risk.
Study context
- Population
- Adults with refractory septic shock requiring norepinephrine > 0.2 mcg/kg/min or epinephrine, medical ICUenrolled
- Participants
- 130 adults
- Comparison
- Adjunctive terlipressin vs placebo
- Terlipressinn = 66
- Placebon = 64reference
- Primary endpoint
- Proportion achieving MAP ≥ 65 mmHg with total catecholamine equivalent dose below 0.2 mcg/kg/min
- Follow-up
- 6 h after randomization
Methodological detailssingle-center, prospective, double-blind, placebo-controlled, 1:1 randomisation
- Single-center
- Prospective
- Double-blind
- Placebo-controlled
- 1:1 randomisation
Primary result
As reported in the abstract
Relative risk
1.53
95% CI 1.09–2.14
P = 0.039
By group
Terlipressin vs Placebo
RR 1.53 (95% CI 1.09–2.14); P = 0.039
Further findings
| Outcome | Terlipressin | Placebo | RR (95% CI) | P value | |
|---|---|---|---|---|---|
| 28-day mortality | 60.6% | 64.1% | 0.93 (0.66–1.31) | P = 0.68 | |
| 0.512Relative risk (log scale) |
Safety
Digital ischaemia
- Digital ischemia occurred in 28.8% versus 27.4%; risk not significantly altered by terlipressin
- P = 0.86
Original publication
Adjunctive terlipressin versus placebo in the treatment of refractory septic shock: a randomized, placebo-controlled trial. Crit Care. Published 21 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →